Top Sliver Stocks To Own Right Now

Netflix (NASDAQ: NFLX  ) CEO Reed Hastings got into hot water last summer. A couple of his personal Facebook (NASDAQ: FB  ) updates contained information that some considered to be of material interest to shareholders. Indeed, one update on sky-high streaming hours certainly moved the Netflix stock.

Some thought this was an inappropriate use of social media. An SEC investigation was started, not to mention several class action lawsuits. Tweets and Facebook posts shouldn't be required reading for investors! These outlets have no business affecting Netflix share prices!

The storm has mostly blown over. The SEC dropped its investigation last week, but also provided Netflix with guidelines on what social media is kosher or not for business disclosures. And last night, Netflix provided a handy list to keep investors informed -- published as an 8-K SEC filing, just to be sure.

Top 10 Oil Service Stocks To Watch Right Now: Gotesco Land Inc (GO)

Gotesco Land, Inc. (GLI) is the holding company of Ever-Gotesco Group of Companies for its property development projects. The Company is primarily engaged in acquiring, developing, administering, selling, managing or otherwise dealing in real estate transactions. The Company, together with its subsidiaries, operates in two business segments. The real estate segment is engaged in the development and sale of real properties. The leasing segment is egnaged in the leasing of clubhouse and resort facilities. As of December 31, 2011, the Company's wholly owned subsidiaires included Chateau Royale Sports & Country Club, Inc. (CRSCCI), Evercrest Cebu Golf Club & Resort, Inc. (ECGCRI), Gulod Resort, Inc. (GRI), Multiresources Holding Company, Inc. (MHCI) and Nasugbu Resort, Inc. (NRI). Advisors' Opinion:

• [By Mark Salzinger, Editor and Publisher, No-Load Fund Investor]

  The former are called General Obligation (GO) bonds, while the latter are generally called revenue bonds. In the old days, GOs were considered safer, because they were backed by the full taxing authority of the issuer. Now, revenue bonds are more in vogue.

• [By Emerging Opportunities]

  Gross output (GO) measures the total output of an economy, including investments made by businesses in order to produce their goods, such as capital outlays on new equipment, raw materials, or other business-to-business transactions. In Structure, Skousen makes the case that modern economists downplay the importance of the business sector in the economy and overstate the importance of consumer spending. He believes that the GDP should not be used as the sole measure of economic activity.

Top Sliver Stocks To Own Right Now: Boston Scientific Corp (BSX)

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. During the year ended December 31, 2011, its products were offered for sale by seven core businesses: Interventional Cardiology, CRM, Endoscopy, Peripheral Interventions, Urology/Women�� Health, Neuromodulation, and Electrophysiology. In January 2011, it completed the acquisition of Intelect Medical, Inc. In January 2011, it completed the acquisition of Sadra Medical, Inc. In March 2011, the Company completed the acquisition of Atritech, Inc. In February 2011, it announced the acquisitions of S.I. Therapies and ReVascular Therapeutics, Inc. In January 2011, the Company sold its Neurovascular business to Stryker Corporation. In June 2012, the Company acquired Cameron Health, Inc. of San Clemente, California and, as a result, added to its product portfolio subcutaneous implantable cardioverter defibrillator, called the S-ICD System.

Interventional Cardiology

The Company offers coronary stent product. Coronary stents are tiny, mesh tubes used in the treatment of coronary artery disease, which are implanted in patients to prop open arteries and facilitate blood flow to and from the heart. The Company offers a two-drug platform strategy with its paclitaxel-eluting and everolimus-eluting stent system offerings, and it offers a range of stent sizes. The Company markets its next-generation internally-developed and self-manufactured PROMUS Element stent system in the United States, its Europe/Middle East/Africa (EMEA) region and certain Inter-Continental countries, including China and India. It markets the PROMUS everolimus-eluting stent system, supplied to the Company by Abbott Laboratories, in Japan. It also markets its TAXUS paclitaxel-eluting stent line, including its third-generation TAXUS Element paclitaxel-eluting stent system in the U.nited States, Japan, EMEA and certain Inter-Continental countries.

The Compa! ny markets a line of products used to treat patients with atherosclerosis, a principal cause of coronary artery obstructive disease. Its product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters, embolic protection devices, and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA). The Company markets a family of intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels. The iLab Ultrasound Imaging System continues as its flagship console and is compatible with its line of imaging catheters. The system is designed to enhance the diagnosis and treatment of blocked vessels and heart disorders. Sadra is developing a repositionable and retrievable device for transcatheter aortic valve replacement (TAVR) to treat patients with severe aortic stenosis. The Lotus Valve System consists of a stent-mounted tissue valve prosthesis and catheter delivery system for guidance and placement of the valve. Atritech has developed a device designed to close the left atrial appendage in patients with atrial fibrillation who are at risk for ischemic stroke. The WATCHMAN Left Atrial Appendage Closure Technology, developed by Atritech, is the first device proven in a randomized clinical trial to offer an alternative to anticoagulant drugs, and is approved for use in CE Mark countries.

Cardiac Rhythm Management

The Company develops, manufactures and markets a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, including Implantable cardioverter defibrillator (ICD) systems used to detect and treat abnormally fast heart rhythms (tachycardia) that could result in sudden cardiac death, including implantable cardiac resynchronization therapy defibrillator (CRT-D) systems used to treat heart failure, and implantable pacemaker systems used to manage slow or irregular heart rhyth! ms (brady! cardia), including implantable cardiac resynchronization therapy pacemaker (CRT-P) systems used to treat heart failure. Its product offerings include its COGNIS cardiac resynchronization therapy defibrillator (CRT-D), its TELIGEN ICD systems and its ALTRUA family of pacemaker systems. During 2011, it began the United States launch of its next-generation line of defibrillators, INCEPTA, ENERGEN and PUNCTUA.

Endoscopy

The Company markets a range of products to diagnose, treat and ease a variety of digestive diseases, including those affecting the esophagus, stomach, liver, pancreas, duodenum, and colon. Common disease states include esophagitis, portal hypertension, peptic ulcers as well as esophageal, biliary, pancreatic and colonic cancer. The Company offers the Radial Jaw 4 Single-Use Biopsy Forceps, which are designed to enable collection of large high-quality tissue specimens without the need to use large channel therapeutic endoscopes. Its exclusive line of RX Biliary System devices are designed to provide greater access and control for physicians to diagnose and treat challenging conditions of the bile ducts, such as removing gallstones, opening obstructed bile ducts and obtaining biopsies in suspected tumors. The Company also markets the Spyglass Direct Visualization System for direct imaging of the pancreatico-biliary system. The Spyglass System is a single-operator cholangioscopy device that offers clinicians a direct visualization of the pancreatico-biliary system and includes supporting devices for tissue acquisition, stone management and lithotripsy. Its products also include the WallFlex family of stents, in particular, the WallFlex Biliary line and WallFlex Esophageal line; and in 2011, the Company launched its Advanix Biliary Plastic Stent System and the Expect Endoscopic Ultrasound Aspiration Needle in the United States and certain international markets. Its Resolution Clip Device is an endoscopic mechanical clip designed to treat gastrointestinal bleeding.

T! he Company markets devices to diagnose, treat and ease pulmonary disease systems within the airway and lungs. Its products are designed to help perform biopsies, retrieve foreign bodies from the airway, open narrowings of an airway, stop internal bleeding, and ease symptoms of some types of airway cancers. Its product line includes pulmonary biopsy forceps, transbronchial aspiration needles, cytology brushes and tracheobronchial stents used to dilate narrowed airway passages or for tumor management. Asthmatx, Inc. designs, manufactures and markets a less-invasive, catheter-based bronchial thermoplasty procedure for the treatment of severe persistent asthma. The Alair Bronchial Thermoplasty System, developed by Asthmatx, has both CE Mark and Food and Drug Administration (FDA) approval and is the first device-based asthma treatment approved by the FDA.

Peripheral Interventions

The Company sells various products designed to treat patients with peripheral disease, including a line of medical devices used in percutaneous transluminal angioplasty and peripheral vascular stenting. Its peripheral product offerings include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters. In 2010 and 2011, it launched several of its products internationally, including the EPIC self-expanding nitinol stent system in certain international markets, and the Carotid WALLSTENT stent system in Japan. The Company launched three new peripheral angioplasty balloons in 2011, including its next-generation Mustang percutaneous transluminal angioplasty (PTA) balloon, its Coyote balloon catheter, a highly deliverable and ultra-low profile balloon dilatation catheter designed for a range of peripheral angioplasty procedures and its Charger PTA Balloon Catheter, a 0.035 inch percutaneous transluminal angioplasty balloon catheter designed for post-stent dilatation, as well as conventional balloon angioplasty to open blocked peripheral arteries. The Company has commenced a limited ma! rket rele! ase of its OFFROAD re-entry catheter system in certain international markets, and in February 2012, it launched its TRUEPATH intraluminal CTO device in the United States.

The Company sells products designed to treat patients with non-vascular disease. Its non-vascular suite of products include biliary stents, drainage catheters and micro-puncture sets designed to treat, diagnose and ease various forms of benign and malignant tumors. The Company continues to market its extensive line of Interventional Oncology product solutions, including the Renegade HI-FLO Fathom microcatheter and guidewire system and Interlock - 35 Fibered IDC Occlusion System for peripheral embolization. The Company�� FilterWire EZ Embolic Protection System is a filter designed to capture embolic material that may become dislodged during a procedure, which could otherwise travel into the microvasculature where it could cause a heart attack or stroke. It is commercially available in the United States, its EMEA region and certain Inter-Continental countries for multiple indications, including the treatment of disease in peripheral, coronary and carotid vessels. It is also available in the United States for the treatment of saphenous vein grafts and carotid artery stenting procedures.

Urology/Women�� Health

The Company�� Urology/Women�� Health division develops, manufactures and sells devices to treat various urological and gynecological disorders. The Company sells a variety of products designed to treat patients with urinary stone disease, stress urinary incontinence, pelvic organ prolapse and excessive uterine bleeding. The Company offers a line of stone management products, including ureteral stents, wires, lithotripsy devices, stone retrieval devices, sheaths, balloons and catheters.

The Company markets a range of devices for the treatment of conditions, such as female urinary incontinence, pelvic floor reconstruction (rebuilding of the anatomy to its original state), and ! menorrhag! ia (excessive menstrual bleeding). It offers a breadth of mid-urethral sling products, sling materials, graft materials, pelvic floor reconstruction kits, and suturing devices. The Company markets its Genesys Hydro ThermAblator (HTA) system, a next-generation endometrial ablation system designed to ablate the endometrial lining of the uterus in premenopausal women with menorrhagia. The Genesys HTA System features a smaller and lighter console, simplified set-up requirements, and an enhanced graphic user interface and is designed to improve operating performance.

Neuromodulation

The Company within its Neuromodulation business markets the Precision Spinal Cord Stimulation (SCS) system, used for the management of chronic pain. In 2011, the Company launched its Clik Anchor for its Precision Plus SCS System, a rechargeable SCS device for chronic pain management. During 2011, it received FDA approval for and launched the Infinion 16 Percutaneous Lead, a 16-contact percutaneous lead. The Company also markets the Linear 3-4 and Linear 3-6 Percutaneous Leads for use with its SCS systems, which are designed to provide physicians more treatment options for their chronic pain patients. Intelect Medical, Inc. is a development-stage company developing advanced visualization and programming for the Vercise system.

Electrophysiology

The Company within its Electrophysiology business develops less-invasive medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart. Included in its product offerings are radio frequency (RF) generators, steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Its products include the Blazer and Blazer Prime line of temperature ablation catheters, designed to deliver enhanced performance, responsiveness, and durability. Its cooled ablation portfolio includes the closed-loop irrigated catheter on the market, the Chilli II cooled! ablation! catheter, and the newly launched Blazer Open-Irrigated ablation catheter with a Total Tip Cooling Design.

The Company competes with Abbott Laboratories, Medtronic, Inc., St. Jude Medical, Inc. and Johnson & Johnson.

Advisors' Opinion:

• [By Holly LaFon]

  The stocks he did buy in the fourth quarter are almost all large positions. The largest, Boston Scientific (BSX), is 5.4 percent of his portfolio. He bought 7,797,503 shares at an average price of $5.50. The stock has declined over 20 percent in the last year and 65 percent over the last five years. The company has had volatile free cash flow over the last ten years and declining annual revenue since 2007. However, it has cut expenses (including jobs), is investing in China, and is launching two dozen new devices in 2012, in an effort to increase earnings by double digits in the next five years. Year to date, the stock is up 12 percent.

• [By Ben Levisohn]

  While shares of Volcano have dropped 15% to $20.74, large-cap medical device companies are having a solid day. Boston Scientific (BSX) has gained 1.4% to 11.74, St. Jude Medical (STJ) has risen 0.9% to $48.13 and Medtronic (MDT) has ticked up 0.1% to $57.73.

• [By Holly LaFon]

  ��Boston Scientific Corp. (BSX), a medical device manufacturer, recently reported its first quarter of growth in more than three years, while also raising its earnings outlook. An emerging pipeline of new products offers the potential for continued improvement and the potential to return to mid-single digit revenue growth.

• [By Max Macaluso, Ph.D.]

  Shares of Abbott Laboratories (NYSE: ABT  ) may be up 10.7% since the start of 2013, but this stock has lagged behind the S&P 500 index and many of its health care peers, including Boston Scientific (NYSE: BSX  ) and�Johnson & Johnson. Abbott's next big catalyst will be its second-quarter results, which are set to be revealed tomorrow morning, but will earnings wow investors, or will they miss estimates and disappoint?

Top Sliver Stocks To Own Right Now: Splunk Inc (SPLK)

Splunk Inc. (Splunk) provides a software platform. Splunk�� software collects and indexes data regardless of format or source, and enables users to search, correlate, analyze, monitor and report on this data, all in real time. Its software is designed to help users in various roles, including information technology (IT) and business professionals, analyze machine data and realize real-time visibility into and about their organization's operations. The core of its software is a machine data engine, comprised of collection, indexing, search and data management capabilities. Its software can collect and index terabytes of information daily, irrespective of format or source. As of January 31, 2012, the Company had approximately 3,700 customers.

The Company�� software enables users to identify problems, get answers and gain new business insights and intelligence from machine data across their globally distributed enterprise all through one platform. Its software contains features and functionality, such as Universally collect, index, store and archive any machine data, from any source, search and investigate, user-friendly interface, knowledge store, monitor and alert, report and analyze, custom dashboards and views, platform extensibility, role-based access and controls.

The Company competes with BMC Software, Inc., CA, Compuware, HP, IBM, Intel, Microsoft Corporation, Quest Software, Adobe Systems, Google, Webtrends, EMC, Oracle and SAP.

Advisors' Opinion:

• [By Dan Caplinger]

  On Thursday, Splunk (NASDAQ: SPLK  ) will release its latest quarterly results. With the company's stock having rebounded sharply from a post-IPO slump last year, investors have to wonder when Splunk will finally become profitable.

• [By Jake L'Ecuyer]

  Shares of Splunk (NASDAQ: SPLK) got a boost, shooting up 22.70 percent to $73.50 after the company reported upbeat results for the third quarter and issued a strong forecast.

• [By Anders Bylund]

  Data analysis specialist Splunk's (NASDAQ: SPLK  ) first-quarter report was a bit of a head-scratcher.

  Splunk shares took a 4% nosedive when the report was published, because its revenues came in strong but earnings were merely adequate. Revenue jumped 54% year over year to $57.2 million, easily topping Wall Street's $54 million target. The adjusted $0.06 loss per share was right in line with analyst expectations. That's just not good enough when your last three reports absolutely crushed Street targets on the bottom line, at least in percentage terms. The backlash was strong enough to suck data analysis rival TIBCO Software (NASDAQ: TIBX  ) down into a 1.5% drop in early Friday trading. There must be something wrong with this supposedly robust market, right?

Top Sliver Stocks To Own Right Now: OCZ Technology Group Inc(OCZ)

OCZ Technology Group, Inc. designs, develops, manufactures, and distributes computer components for computing devices and systems worldwide. It primarily offers solid state drives, flash memory storage, memory modules, thermal management solutions, AC/DC switching power supply units, and computer gaming solutions. The company?s products are used in industrial equipment and computer systems; computer and computer gaming solutions; mission critical servers and high end workstations; personal computer (PC) upgrades to extend the useable life of existing PCs; high performance computing and scientific computing; video and music editing; home theatre PCs and digital home convergence products; and digital photography and digital image manipulation computers. OCZ Technology Group, Inc. offers its products to retailers, on-line retailers, original equipment manufacturers, systems integrators, and distributors. The company was founded in 2002 and is headquartered in San Jose, Califo rnia.

Advisors' Opinion:

• [By Rich Duprey]

  The not-so-great and wonderful OCZ
  There was no company-specific news that caused solid-state-drive maker OCZ Technology (NASDAQ: OCZ  ) to fall almost 8% Wednesday. But an article that appeared on Seeking Alpha �questioning whether the company had six months or less to live before it filed for bankruptcy seemed to coincide with its fall.

Top Sliver Stocks To Own Right Now: HSBC Holdings PLC (HSBC)

HSBC Holdings plc (HSBC), incorporated on January 1, 1959, is a global banking and financial services organizations. As of December 31, 2012, it provided a range of financial services to around 58 million customers through four global businesses: Retail Banking and Wealth Management, Commercial Banking, Global Banking and Markets, and Global Private Banking. Its international network covers 81 countries and territories in six geographical regions; Europe, Hong Kong, Rest of Asia-Pacific, Middle East and North Africa, North America and Latin America. As of December 31, 2012, the Company had an international network of some 6,600 offices in 81 countries and territories in six geographical regions; Europe, Hong Kong, Rest of Asia-Pacific, Middle East and North Africa (��ENA��, North America and Latin America. On May 20, 2012, HSBC Holdings PLC's wholly owned subsidiary HSBC Bank USA, N.A. and other wholly owned subsidiaries, sold 195 retail branches to First Niagara Bank, N.A. (First Niagara). In May 2012, the Company�� 70.03% owned subsidiary, HSBC Bank Malta plc, sold its card acquiring business to HSBC Merchant Services Ltd. In June 2012, the Company�� indirect wholly owned subsidiary, HSBC Iris Investments (Mauritius) Ltd, sold its 4.73% interest in Axis Bank Limited and 4.74% interest in Yes Bank Limited. In July 2012, its subsidiary, HSBC Europe (Netherlands B.V.), sold its 100% interest in HSBC Credit Zrt, to CentralFund Kockazati Tokealap. On March 31, 2013, Enstar Group Ltd�� subsidiary completed the acquisition from Household Insurance Group Holding Company of HSBC Insurance Company of Delaware and Household Life Insurance Company of Delaware, as well as its three subsidiary insurers.

The Company�� principal banking operations in Europe are HSBC Bank plc in the UK, HSBC France, HSBC Bank A.S. in Turkey, HSBC Bank Malta p.l.c., HSBC Private Bank (Suisse) SA and HSBC Trinkaus & Burkhardt AG. Through these subsidiaries it provides a range of banking, treasury and financia! l services to personal, commercial and corporate customers across Europe. HSBC�� banking subsidiaries in Hong Kong are The Hongkong and Shanghai Banking Corporation Limited and Hang Seng Bank Limited.

The Company offers a range of banking and financial services in the People�� Republic of China, mainly through its local subsidiary, HSBC Bank (China) Company Limited. It also participates indirectly in mainland China through its primary associate, Bank of Communications. Outside mainland China, it conducts business in 21 countries and territories in the Rest of Asia-Pacific region, primarily through branches and subsidiaries of The Hongkong and Shanghai Banking Corporation.

In the Middle East, the Company has network of branches of HSBC Bank Middle East Limited, together with HSBC�� subsidiaries and associates. Its North American businesses are located in the United States, Canada and Bermuda. Operations in the United States are conducted through HSBC Bank USA, N.A., and HSBC Finance, a national consumer finance company based near Chicago. HSBC Markets (USA) Inc. is the intermediate holding company of, inter alia, HSBC Securities (USA) Inc. HSBC Bank Canada and HSBC Bank Bermuda operate in their respective countries.

The Company�� operations in Latin America consists of HSBC Bank Brasil S.A.-Banco Multiplo, HSBC Mexico, S.A., HSBC Bank Argentina S.A. and HSBC Bank (Panama) S.A. In addition to banking services, it operates insurance businesses in Brazil, Mexico, Argentina, Panama and a range of smaller markets.

Retail Banking and Wealth Management

Retail Banking and Wealth Management (RBWM) take deposits and provide transactional banking services to enable customers to manage their day-to-day finances and save for the future. It offers credit facilities to assist customers in their short or longer-term borrowing requirements; and we provide financial advisory, broking, insurance and investment services to help them to manage and pro! tect thei! r financial futures. It develops products designed to meet the needs of specific customer segments, which may include a range of different services and delivery channels. Its customer offerings include deposits and account services; credit and lending, both secured and unsecured, and financial advisory, broking, life insurance manufacturing and asset management.

The Company offers services through four principal channels: branches, self-service terminals, telephone service centres and digital (Internet and mobile). Customers can transact with the bank through a combination of these channels. Its offers include HSBC Premier, HSBC Advance, Wealth Solutions & Financial Planning and Basic Banking. HSBC Premier provide preferential banking services and global recognition to its mass affluent customers and their immediate families. Customers can access emergency travel assistance, priority telephone banking and an online global view of their Premier accounts around the world. HSBC Advance provides a range of preferential products and services to simplify the banking needs of customers and to help them manage and plan their money to achieve their financial goals and ambitions. Wealth Solutions & Financial Planningis a financial planning process designed around individual customer needs to help its clients to protect, grow and manage their wealth through investment and wealth insurance products manufactured by Global Asset Management, Global Markets and HSBC Insurance and by selected third-party providers. Basic Banking provides banking products and services using global product platforms and globally set service standards.

Commercial Banking

The Company segment�� its Commercial Banking Business (CMB) into Corporate, to serve both Corporate and Mid-Market companies, and Business Banking, to serve the small and medium-sized enterprises (SME��) sector. It provides support to companies as they expand both domestically and internationally, and ensures a focus on the busine! ss bankin! g segments. It offers a range of financing, both domestic and cross-border, including overdrafts, receivables finance, term loans and syndicated, leveraged, acquisition and project finance. Asset finance is offered in selected sites. The Company provides the services and finance its clients need throughout the trade cycle including; letters of credit, collections, guarantees; receivables finance; supply chain solutions; commodity and structured finance; and risk distribution. HSBC is supporting the development of renminbi as a trade currency, with renminbi capabilities in more than 50 markets. It is a provider of domestic and cross-border payments, collections, liquidity management and account services offering local, regional and global solutions delivered through e-enabled platforms designed to address the current and future needs of its clients. The Company offers business and financial protection, trade insurance, employee benefits, corporate wealth management and a variety of other commercial risk insurance products in selected countries.

Global Banking and Markets

Global Banking and Markets (GB&M) provides tailored financial solutions to government, corporate and institutional clients and private investors globally. Managed as a global business, GB&M operates a long-term relationship management approach to build a understanding of clients��financial requirements. Sector-focused client service teams consisting of relationship managers and product specialists develop financial solutions to meet individual client needs. GB&M is managed as two principal business lines: Global Markets, and Global Banking.

Global Markets operations consist of treasury and capital markets services. Products include foreign exchange; currency, interest rate, bond, credit, equity and other derivatives; government and non-government fixed income and money market instruments; precious metals and exchange-traded futures; equity services; distribution of capital markets instruments, a! nd securi! ties services, including custody and clearing services and funds administration to both domestic and cross-border investors. Global Banking offers financing, advisory and transaction services. Its products include capital raising, advisory services, bilateral and syndicated lending, leveraged and acquisition finance, structured and project finance, lease finance and non-retail deposit taking; international, regional and domestic payments and cash management services; and trade services for corporate clients.

Global Private Banking

Global Private Banking (GPB) provides investment management and trustee solutions to high net worth individuals and their families globally. Private Banking services consists of multicurrency and fiduciary deposits, account services, and credit and specialist lending. GPB also accesses HSBC�� universal banking capabilities to offer products and services such as credit cards, Internet banking, and corporate and investment banking solutions. Investment Management comprises advisory and discretionary investment services, as well as brokerage across asset classes. This includes a range of investment vehicles, portfolio management, security services and alternatives. Private Trust Solutions comprise trusts and estate planning, designed to protect wealth and preserve it for future generations through structures tailored to meet the individual needs of each client.

Advisors' Opinion:

• [By Benjamin Shepherd]

  In the meantime, though, 13 percent of the fund�� assets are devoted to health care with another 12.8 percent to consumer defensive names, helping to reduce the volatility of its portfolio. While the fund�� beta is roughly in line with the broader European market, its standard deviation is actually slightly lower while producing a superior return. It also offers an attractive 3.9 percent yield despite its focus on large, mature companies such as Nestle (OTC: NSRGY), Novartis (NYSE: NVS), HSBC (NYSE: HSBC) and BP (NYSE: BP).
  
  With more good news coming from Europe every day, Vanguard European Stock Index rates a buy up to 65.
  
  

Top Sliver Stocks To Own Right Now: Acciona SA (ANA)

Acciona SA is a Spain-based holding company active in the construction and engineering industry. It is engaged in renewable energy, water services and infrastructure sectors.The Company operates through six business areas; Infrastructure involves the construction, engineering and transportation, as well as hospital concessions; Real Estate is active in the development of real estate properties and parking lot operations; Energy involves the generation, distribution and sale of energy; Transportation and Logistics Services provides integrated transport services for passengers and cargo; Environmental and Urban Services is engaged in activities related to services in the urban scope and environment protection, such as the execution of all types of activities in the water supply; Other Activities is engaged in the provision of services related to funds management and financial intermediation, as well as wine production, among others. Advisors' Opinion:

• [By Sarah Jones]

  Iberdrola SA (IBE), Spain�� biggest power company, fell 3.4 percent to 3.87 euros. Endesa SA (ELE) slumped 4.6 percent to 16 euros, while Acciona SA (ANA), which owns more than 4 gigawatts of wind farms in the country, tumbled 8.5 percent to 37.95 euros. Red Electrica Corp. slid 7.5 percent to 38.34 euros.